Lyell Immunopharma Appoints Smital Shah as Chief Financial and Business Officer

summarizeSummary

Lyell Immunopharma announced the appointment of Smital Shah as its new Chief Financial and Business Officer, effective March 9, 2026, bringing extensive biotech finance and business development experience.

check_boxKey Events

• New Chief Financial and Business Officer Appointed

  Smital Shah has been appointed as the Company's Chief Financial and Business Officer and principal financial officer, effective March 9, 2026. Lynn Seely, M.D., previously served as interim principal financial officer.

• Experienced Biotech Finance Leader

  Ms. Shah brings a strong background, having served as Chief Business and Financial Officer of ProQR Therapeutics and managed debt and investment portfolios at Gilead Sciences, Inc. She also has experience as an investment banker in biotechnology.

• Compensation Package Detailed

  Ms. Shah will receive an annual base salary of $500,000, a target annual bonus of up to 50% of her base salary, and a stock option for 140,000 shares of common stock, vesting over four years.

auto_awesomeAnalysis

Lyell Immunopharma has appointed Smital Shah as its new Chief Financial and Business Officer and principal financial officer. This is a significant executive appointment, bringing an experienced financial leader to a key C-suite role. Ms. Shah's extensive background in biotech finance, including a previous CFO role at ProQR Therapeutics and experience at Gilead Sciences and as an investment banker, strengthens the company's leadership team. The compensation package, including a substantial stock option grant, aligns her incentives with long-term shareholder value. This move is generally positive, signaling stability and a dedicated focus on financial strategy and business development.